PTH Replacement Therapies: Current Options and What’s Ahead

Hypoparathyroidism remains one of the few endocrine conditions with limited hormone replacement options—until recently. While traditional care has focused on calcium and active vitamin D, newer therapies aim to replace the missing hormone itself: parathyroid hormone (PTH).

This blog reviews the three FDA-approved options for PTH replacement and introduces several emerging therapies in clinical trials. Each therapy varies in duration, molecular design, and supplement dependence, which shapes clinical decisions and patient outcomes.

FDA-Approved PTH Therapies: A Side-by-Side Comparison

The table below summarizes the three key therapies—Natpara, Forteo, and YORVIPATH—with attention to their origin, approval status, and role in clinical practice.

Comparison of PTH Replacement Therapies for Hypoparathyroidism

Feature	Natpara	Forteo	YORVIPATH
Generic Name	Recombinant human PTH (1–84)	Teriparatide (recombinant PTH 1–34)	Palopegteriparatide (modified PTH 1–34 prodrug)
Brand Name	Natpara	Forteo	YORVIPATH
Molecule Type	Full-length PTH (1–84)	PTH fragment (1–34)	Pegylated PTH 1–34 prodrug (TransCon PTH)
FDA Approval	Yes (for hypoparathyroidism)	Yes (for osteoporosis only)	Yes (for hypoparathyroidism)
Indication	Chronic hypoparathyroidism	Osteoporosis (off-label for hypoPT)	Chronic hypoparathyroidism
Dosing Frequency	Once daily injection	Once daily injection	Once daily injection
Half-life / Duration	Short half-life	Short half-life	Sustained 24-hour physiological release
Supplement Use	Calcium and calcitriol often still needed	Often still needed	Often eliminates need for supplements
Availability	Discontinued due to cartridge safety (2024–2025)	Available	FDA-approved in 2024; expected launch in 2025
Use in Hypoparathyroidism	Previously standard (before withdrawal)	Used off-label in select cases	Intended for chronic hypoPT treatment
Clinical Features	Mimics natural PTH profile	Short-acting; flexible titration	Steady-state coverage; more physiological
Limitations / Risks	Market withdrawal; device concerns; short half-life	Not FDA-approved for hypoPT	Early adoption phase; dosing/device variability possible
Common Side Effects	Nausea, joint pain, dizziness	Nausea, dizziness, leg cramps	Injection site reactions, headache
Additional Notes	Boxed warning for osteosarcoma; immunogenicity potential	Long safety record in osteoporosis	Long-acting design may simplify management

Understanding Each Option

• Natpara was the first therapy FDA-approved specifically for hypoparathyroidism. It offered full-length hormone replacement but was withdrawn due to cartridge safety concerns, not because of lack of effectiveness.
• Forteo remains widely available and FDA-approved for osteoporosis, not hypoparathyroidism. However, parathyroid specialists sometimes use it off-label in carefully selected cases where calcium balance remains unstable.
• YORVIPATH, approved in 2024, represents a meaningful shift. It uses a prodrug mechanism to release PTH gradually over 24 hours. It offers more stable calcium levels and potentially reducing the need for supplemental calcium or calcitriol.

What’s Coming Next: Therapies in the Pipeline

Several experimental therapies aim to further improve the ease, safety, and physiologic realism of PTH replacement. These include oral options, longer-acting injectables, and tissue-targeted designs. Here’s a snapshot of the leading candidates:

Current PTH Replacement Therapies in Clinical Trials

Name / Code	Status	Developer	Mechanism / Notes
Eneboparatide (AZP-3601)	Phase III	Amolyt Pharma → Acquired by AstraZeneca	Peptide PTH receptor 1 agonist. Aims to normalize calcium, reduce supplements, and lower urinary calcium.
EXT608 (aka PTH-CBD)	Early development	Extend Biosciences	Long-acting PTH analog with collagen-binding domain. Seeks sustained calcium rise with reduced calciuria.
EnteraBio Oral PTH (EBP05)	Phase 2	EnteraBio	Oral PTH (1–34) tablet. Targets improved GI absorption of PTH with convenient dosing.

Why Holistic, Individualized Care Matters

Choosing or transitioning to PTH therapy isn’t just about replacing a hormone—it’s about restoring balance across calcium, phosphorus, bone health, and kidney function. For some, daily supplements may be enough. For others, especially those with fluctuating calcium levels or long-term complications, PTH replacement offers a more physiologic path forward.

At our practice in Montgomery County, Maryland, we approach hypoparathyroidism with care from multiple angles—integrating labs, lifestyle, and endocrine guidance to develop a smart, long-term strategy for each individual. Our virtual care option allows us to support patients across and beyond the region.